Alkaloid capable of reversing resistance of lung cancer to cisplatin

An alkaloid and drug resistance technology, applied in the field of medicine, can solve the problems of limiting the curative effect of combined chemotherapy, poor prognosis of patients, and survival rate of less than 15%

Inactive Publication Date: 2018-12-21
普瑞赛森(山东)生物医学科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

NSCLC is prone to regional lymph node metastasis and hematogenous dissemination, and the prognosis of patients is poor, with a 5-year survival rate of less than 15%.
[0003] Cisplatin (DDP) is the first-line chemotherapy drug after lung cancer surgery, and natural and acquired drug resistance limit the efficacy of cisplatin-based combination chemotherapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alkaloid capable of reversing resistance of lung cancer to cisplatin
  • Alkaloid capable of reversing resistance of lung cancer to cisplatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] The following describes the essential content of the present invention in detail with reference to the drawings and embodiments, but the protection scope of the present invention cannot be limited by this.

[0025] 1. Experimental materials

[0026] The alkaloids studied and tested are prepared according to conventional methods and literature methods, and are divided into five categories according to chemical structures. The specific chemical structures and numbers are shown in the following table.

[0027]

[0028] Lung cancer cell line H460 was purchased from ATCC, and DMEM medium and fetal bovine serum were purchased from GIBCO.

[0029] 2. Experimental method

[0030] 1. Cell culture

[0031] After routine resuscitation of human lung cancer cell line H460, use DMEM medium containing 10% FBS, 50U / ml streptomycin, 50U / ml penicillin and 4mmol / L L-glutamine at 37℃, 5% CO 2 Culture under the conditions, changing the medium every 2 to 3 days.

[0032] 2. Construction of cisplatin res...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an alkaloid capable of reversing the resistance of lung cancer to cisplatin. Cisplatin (DDP) is a first-line chemotherapy drug used after lung cancer surgery. cisplatin-based combined chemotherapy has an efficacy restricted by the natural and acquired drug-resistance; therefore, it is needed to develop drugs to reverse the resistance of lung cancer to cisplatin. It is foundthat compounds TA-1, TA-2, TB-1, TB-2, TB-3, TC-1, TD-1, TE-1 and TE-2 are able to effectively reverse the resistance of lung cancer cells to cisplatin, among which TC-1 and TD-1 are capable of not only reversing drug resistance, but also enhancing the sensitivity of the lung cancer cells to cisplatin, but a compound B-4 does not have this effect.

Description

Technical field [0001] The invention belongs to the field of medicine and relates to an alkaloid for reversing the cisplatin resistance of lung cancer. Background technique [0002] Lung cancer is the most common malignant tumor of the respiratory system, and its morbidity and mortality rate rank first among malignant tumors, and have a rising trend year by year. From a clinical perspective, combined with the histological and biological characteristics of tumor cells, lung cancer is generally divided into two categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). About 85% of lung cancers are NSCLC. NSCLC is prone to regional lymph node metastasis and blood-borne dissemination. The prognosis of patients is poor, and the 5-year survival rate is less than 15%. [0003] Cisplatin (DDP) is the first-line chemotherapy drug after lung cancer surgery. Natural and acquired resistance limit the efficacy of cisplatin-based combination chemotherapy. Therefore, it...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/439A61K33/24A61P11/00A61P35/04
CPCA61K31/439A61K33/24A61P11/00A61P35/04
Inventor 焦立英吕石翠王兆丽
Owner 普瑞赛森(山东)生物医学科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap